Background: Tumor stromal interactions have been shown to be the driving force behind the poor prognosis associated with aggressive breast tumors. These interactions, specifically between tumor and the surrounding extracellular matrix (ECM), and between tumor and vascular endothelial cells, promote tumor formation, angiogenesis, and metastasis to distant tissues. In this study, we develop an in vitro vascularized breast tumor platform that allows for investigation of tumor-stromal interactions in three aggressive breast tumor derived cell lines: MDA-IBC3, SUM149, and MDA-MB-231. Methods: The in vitro breast tumor platform consists of a cylindrical endothelial vessel, surrounded by a tumor cell-seeded collagen matrix allowing for direct interactions between endothelial and cancer cells. The platform recapitulates key characteristics of breast tumors, including increased vascular permeability, vessel sprouting, and ECM remodeling. Morphological and quantitative analysis reveals differential effects from each tumor cell type on endothelial coverage, permeability, expression of vascular endothelial growth factor (VEGF), and collagen remodeling. Results: The triple negative tumors, SUM149 and MDA-MB-321, resulted in a significantly (p <0.05) higher endothelial permeability to 70 kda dextran and decreased endothelial coverage of the vessel lumen compared to the control TIME only in vitro vascularized platform. SUM149/TIME platforms were 1.3 fold lower (p<0.05), and MDA-MB-231/TIME platforms were 1.5 fold lower (p<0.01) in endothelial coverage compared to the control TIME only platform. HER2+ MDA-IBC3 tumor cells expressed high levels of VEGF (p<0.01) and induced vessel sprouting without the influence of additional angiogenic supplements or supporting cells. Vessels sprouting was tracked over a 3 week period and with increasing time exhibited more pronounced formation of multiple vessel sprouts with branches that invaded into the collagen ECM and surrounded cluster of MDA-IBC3 cells. Both the IBC cell lines, SUM149 and MDA-IBC3, resulted in a collagen ECM with significantly greater porosity with 1.6 and 1.1 fold higher compared to control, p<0.01.
impact treatment response [46] [47] [48] [49] [50] [51] [52] . We focused on optimizing tumor-endothelial cell assays and effects in aggressive IBC (SUM149 and MDA-IBC3) and non-IBC invasive ductal carcinoma (MDA-MB-231) breast cancer cells lines. The 3D in vitro vascularized platform was utilized to model both tumor cell growth with an optimized intact endothelial cell structure. Conditions representative of in vivo tumor vasculature interface such as physiological flow and associated shear stress were utilized for development of a continuous, aligned and functional endothelium allowing for tumor-endothelial-ECM interactions. We investigated differential effects by cell line on endothelial coverage, permeability, and matrix porosity as well as cytokine secretion to demonstrate this platform can be used to study spatial and functional interactions not easily investigated in existing models. Additionally, we recreated emboli formation and vascular nesting of tumor emboli, behavior characteristic of in vivo IBC phenotype. These platforms provide us with a tool to elucidate disease dynamics of aggressive breast cancer tumors where tumor-stroma interactions are the driving force behind tumor development and progression.
Materials and Methods

Cell Culture
Human breast carcinoma cell line MDA-MB-231(ATCC® HTB-26™) breast carcinoma, human breast inflammatory cancer cells MDA-IBC3 and SUM149, and telomerase-immortalized human microvascular endothelial (TIME) cells were used in this study. MDA-MB-231 and SUM149 are triple negative cell lines while MDA-IBC3 cells are negative for hormone receptors but overexpress human epidermal growth factor receptor 2 (HER2). Stable fluorescent MDA-MB-231 (GFP) and TIME (mKate) cells were a generous gift from Dr. Shay Soker at the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC). MDA-IBC3 and SUM149 IBC cell lines labeled with GFP were kindly provided by Dr. Wendy Woodward at MD Anderson Cancer Center (Houston, TX).
MDA-MB-231 cells were cultured in Dulbecco's Modified Eagle's medium, nutrient mixture F-12 (DMEM/F12) (Sigma Aldrich) supplemented with 1% penicillin-streptomycin (P/S) (Invitrogen), and 10 % fetal bovine serum (FBS). MDA-IBC3 and SUM149 cells were cultured in Ham's F-12 media supplemented with 10% FBS, 1% antibiotic-antimycotic, 1 µg/ml hydrocortisone, and 5 µg/ml insulin. TIME cells were cultured in EBM-2 endothelial growth media supplemented with a growth factor BulletKit (Lonza CC-4176). All cell cultures utilized in this study were maintained in a 5% CO2 atmosphere at 37°C in an incubator.
In vitro 3D Tumor Platform Fabrication
The in vitro 3D tumor microfluidic platforms utilized in this study were composed of collagen type I matrix seeded with either MDA-MB-231, MDA-IBC3, or SUM 149 with a hollow channel seeded with RFP labeled TIME cells housed in a polydimethylsiloxane (PDMS) scaffold. Collagen type I extracted from rat tails was prepared following published protocols to produce stock collagen concentration of 14 mg/ml which was then neutralized with a solution consisting of 10x DMEM, 1N NaOH, and 1x DMEM to produce a final collagen concentration of 7 mg/ml comparable to stiffness of breast tumors [53] [54] [55] [56] . GFP labeled IBC and non-IBC cells were seeded at a density of 1x10 6 cells/mL in the 7 mg/ml neutralized collagen solution and polymerized around a 22G needle at 37°C for 25 minutes. After polymerization, the needle was removed, and the resulting hollow void was filled with a solution of 2x10 5 TIME cells to form an endothelialized vessel lumen. The size of the needle can be varied to mimic vessels of varying sizes in a controllable manner. Flow was introduced using a syringe pump system and a 72 hour graded flow protocol was used to establish a confluent endothelium as we have previously published [53, [56] [57] [58] . Briefly, flow was perfused to expose the endothelium to wall shear stress (WSS) (τ) of 0.01 dyn/cm 2 for 36 hours followed by a gradual increase in WSS to 0.1 dyn/cm 2 for the following 36 hours. After completion of the 72 hour graded flow protocol, the in vitro vascularized platforms were exposed to 1 dyn/cm 2 for 6 hours.
Endothelial Sprouting
MDA-IBC3/TIME in vitro vascularized platforms were cultured for an additional three weeks following the 78 hour graded flow protocol in order to track endothelial sprouting. 3D images of the platforms were acquired using Leica TCS SP8 confocal microscope to observe sprout formation and growth. Cross sectional images from the center plane of each channel were used to analyze sprout growth and quantified using ImageJ. Fluorescent intensity histograms for each image were generated using ImageJ's plot profile function. Differences between fluorescence intensity histograms at each time point were quantified using the two-sample KolmogorovSmirnov (K-S) statistic, a distance measure between each sample pair's empirical distribution functions. The K-S statistic was calculated between the baseline fluorescence intensity distribution at Day 0 and subsequent imaging time points and significance was determined using p <0.001.
Immunofluorescent Staining
Endothelial morphology and cell-cell junctions were analyzed by performing immunofluorescent staining for PECAM-1 and F-actin upon completion of the 78 hour graded flow protocol. PECAM-1 (platelet endothelial cell adhesion molecule-1, green) is expressed at endothelial intercellular junctions and functions in the maintenance of endothelial barrier functions [59] . The staining protocol consisted of perfusing the platforms with 4% paraformaldehyde and 0.5% triton-X for fixation and permeabilization of the cell membranes, respectively. Next, the platforms were incubated in 5% BSA followed by overnight incubation with antibodies for PECAM-1 (Abcam, ab215911) and Rhodamine Phalloidin (ThermoFisher, R415).
Endothelium Coverage
Vessel volume occupied by TIME cells was quantified using 3D F-actin stained images of the endothelium in each co-culture platform with LASX image processing software. Platforms containing an endothelial vessel but no cancer cells in the surrounding collagen (TIME only platform) served as a control. Reported values for the co-culture platforms were normalized to the control. Significance of the data was verified using one-way ANOVA and a 95% confidence criterion, p<0.05.
Endothelial Permeability
Endothelial vessel permeability as a function of paracrine signalling between tumor and vasculature was determined by perfusing the channels with 70 kda GFP labelled dextran [57, 60] . Four conditions of the 3D in vitro vascularized tumor platforms were tested: TIME cell only platform, and platforms consisting of co-culture of TIME cells with either MDA-MB-231, MDA-IBC3, or SUM149 cells. After completion of the flow protocol for establishing a confluent endothelium, green fluorescent dextran suspended in serum free media (10 μg/ml) was perfused through the platforms with images taken every five minutes. The average fluorescent intensity was measured from the images and used to determine the diffusion permeability coefficient Pd as previously published [57] . Three samples (n=3) were used for each platform condition with the resulting permeability factor expressed as a mean value ± standard deviation. Significance of the data was verified using one-way ANOVA and a 95% confidence criterion. To visualize the differences in permeability, the vessels were perfused with blue fluorescent particles and time lapse recording of particle perfusion was recorded for 2 hours.
Scanning Electron Microscopy
Scanning electron microscopy (SEM) was performed to determine collagen matrix porosity and observe endothelial adhesion to the collagen matrix. After exposure to 78 hour flow protocol, the platforms were fixed in an aldehyde mixture overnight at room temperature followed by fixation with osmium on ice for 4 hours. Post fixation, the platforms were dehydrated in an ascending series of ethanol solutions (50-70-95%) and then critical point dried by CO2. Platforms were coated with a thin layer of platinum-palladium and high resolution SEM imaging was performed with Zeiss Supra40 SEM-Electron Microscope.
Enzyme-linked Immunosorbent assay
Expression of VEGF, a growth factor known to promote angiogenesis that is excreted from endothelial and tumor cells, was measured using enzyme-linked immunosorbent assays (ELISA) at two points: upon completion of the graded flow protocol (72 hours) for establishing a confluent endothelium and after exposure to WSS of 1 dyn/cm 2 (78 hours). 1 ml samples of perfusion media were collected from the flow outlet and ELISA was performed as per manufacturer's protocol (R&D Systems, DVE00). Significance of the data was verified using one-way ANOVA and a 95% confidence criterion.
Cytokine Analyses
Cytokine analyses for CD31, ANG1, ANG2, TGF-α, bFGF, PDGF-bb, EGF, VEGF-A, VEGFR3, VEGF-C, TNF-α, IL-8, IL-6, IL-6 Rα, MMP9, MMP2, MMP13 were performed using a custom human magnetic luminex assay (R&D Systems). Analyses were performed on platform perfusion effluent on Day 0 (end of graded flow protocol) and 3 according to manufacturer's instructions. Significance of the data was verified using one-way ANOVA and a 95% confidence criterion.
Results
In Vitro IBC Platform Development and Characterization
In vitro 3D Tumor Platform
The 78 hour flow preconditioning protocol with a graded increase in WSS from 0.01 dyn/cm 2 to 1 dyn/cm 2 resulted in a confluent endothelium as shown in Figure 1 . Figure 1 shows the evolution of the vascular endothelium in the TIME only in vitro vascularized platform. The platforms initiated with a vascular channel seeded with rounded clusters of TIME cells (0 hour time point) which began to spread out and elongate (24 and 48 hour time points), followed by proliferation and alignment of the cells in the direction of flow to ultimately form the confluent endothelium observed at the 78 hour time point. The resulting endothelium served as the baseline upon which to evaluate the influence of different cancer cells, IBC and non-IBC, on the surrounding vessel with respect to endothelial morphology, barrier function, and secretion of protumor cytokines. 
Endothelium Integrity
Platforms stained for PECAM-1 and F-actin, as well as SEM analysis illustrated in Figure  3 , demonstrated a compromised endothelium in the in vitro vascularized platforms of SUM149/TIME and MDA-MB-231/TIME. Staining patterns of PECAM-1 (green) and F-actin (red) in Figures 4A and 4B revealed a bright fluorescent signal present continuously across the endothelium in the TIME and MDA-IBC3/TIME in vitro vascularized platforms. However, expression of PECAM-1 and actin in SUM149/TIME and MDA-MB-231/TIME was discontinuous with regions of endothelium lacking any signal (pointed out by white arrows) suggesting formation of intercellular gaps between neighboring endothelial cells which are typical of a leaky endothelium. Additionally, F-actin staining of MDA-IBC3/TIME platform displayed early signs of angiogenic sprouting with TIME cells starting to bud from the borders of the endothelial vessel (boxed areas in Figure 4B ) towards MDA-IBC3 cells replicating another important phenomenon characteristic of in vivo IBC tumors. This behavior was observed only in the MDA-IBC3/TIME platforms. SEM analysis of the endothelium provided high resolution images illustrating endothelial morphology and adhesion to the collagen matrix ( Figure 4C ). Endothelial cells in the TIME only and the MDA-IBC3/TIME platforms showed a tight endothelium with the endothelial cell edges overlapping between neighboring cells, whereas SUM149/TIME and MDA-MB-231/TIME platforms showed voids between adjacent endothelial cells as denoted by the white arrows. Quantitative comparison of endothelial coverage of the lumen, Figure 4 , exhibited a significant decrease in the endothelium coverage in the SUM149/TIME (p<0.05) and MDA-MB-231/TIME (p<0.01) platforms, compared to the MDA-IBC3/TIME and control platform as illustrated in Figure 3 . SUM149/TIME had a 1.3 fold and 1.4 fold decrease, and MDA-MB-231/TIME had a 1.5 and 1.6 fold decrease in endothelial coverage compared to control TIME only control and MDA-IBC3/TIME respectively. There was no significant difference between the control and the MDA-IBC3/TIME platforms. Figure 4 : Endothelium coverage of the vessel lumen of the different co-culture platforms at the 78 hour time point; values have been normalized to the control TIME only platform. TIME only and the MDA-IBC3/TIME platforms had the highest endothelial presence and coverage and MDA-MB-231/TIME platforms has the least endothelial vessel coverage; *p<0.05, ** p<0.01.
Endothelial Permeability
Particle flow images in Figure 5A were taken at 1 hour time point and revealed the difference in the vessel leakiness. The measured effective permeability for TIME only, MDA-IBC3/TIME, SUM149/TIME, and MDA-MB-231/TIME platforms were 0.016 ± 0.002, 0.019 ± 0.002, 0.023 ± 0.002, and 0.025 ± 0.002 respectively, as portrayed in Figure 5B . Vascular permeability of the MDA-MB-231/TIME in vitro vascularized platforms were statistically significant (p <0.05) with 1.6 and 1.3 fold higher permeability than TIME only and MDA-IBC3/TIME in vitro vascularized platforms respectively. SUM149/TIME in vitro vascularized platform also differed significantly from the TIME only platforms (p< 0.05) with a 1.4 fold increase in permeability. 
VEGF ELISA
ELISA measurements for VEGF are illustrated in Figure 6 with the TIME only platform serving as the control. VEGF expression was significantly higher (p < 0.01) at both time points (72 and 78 hour) in MDA-IBC3/TIME in vitro vascularized platforms compared to control (p<0.01) and MDA-MB-231/TIME (p<0.01) and significantly higher than SUM149/TIME at 78 hours (p<0.01). VEGF expression in the MDA-IBC3/TIME in vitro vascularized platform was 1.6 and 2.0 fold higher at the 72 hour time point and 1.3 and 3.0 fold higher at the 78 hour time point compared to TIME only and MDA-MB-231/TIME in vitro vascularized platform respectively. Additionally, there was a trend of decrease in mean VEGF expression in the SUM149/TIME and MDA-MB-231/TIME (not statistically significant) between the 72 and 78 hour time points. 
Matrix Porosity
Tumor cell morphology and matrix porosity measurements are illustrated in Figure  7 . MDA-IBC3 and SUM149 IBC cells displayed an epithelial like rounded phenotype while the MDA-MB-231 presented a mesenchymal like phenotype replicating behavior found in vivo [61] . Porosity measurements in Figure 7B revealed both the IBC in vitro vascularized tumor platforms had a significantly more porous collagen ECM compared to MDA-MB-231/TIME and TIME only in vitro vascularized platforms. SUM149/TIME in vitro vascularized platforms were 1.5 (p<0.01), 1.6 (p<0.01), and 1.3 (p<0.05) fold higher in matrix porosity compared to MDA-MB-231/TIME, TIME only, and MDA-IBC3/TIME in vitro vascularized platforms, respectively. MDA-IBC3 in vitro platforms also showed an increase in ECM porosity of 1.1 (p<0.05) and 1.2 (p<0.01) fold compared to the MDA-MB-231/TIME and TIME only platforms. 
Reproduction of Relevant Tumor Biology and Phenotypic Comparisons to Published Models Longitudinal Characterization of Vascular Sprouting
The resulting sprouting behavior of the MDA-IBC3/TIME in vitro vascularized platforms over the three week period is illustrated in Figure 8 . Figure 8 revealed the ability of the MDA-IBC3/TIME to both promote angiogenic vessel sprouting of the vascular endothelium as well the capability of the platform for spatiotemporal tracking of the sprouting behavior. On day 0, which represents the endothelium formed after the 78 hour graded flow protocol, the endothelium exhibited very few sprouts. At day 4, more sprouts were present with TIME cells extending out from the vessel wall into the collagen. By day 12 and 16, numerous sprouts formed along the length of the vessel wall with multiple branches invading deeper into the collagen ECM. The sprouts extended towards clusters of MDA-IBC3 cells and started to encircle these clusters leading to formation of and proliferation of MDA-IBC3 emboli as pointed out by the white arrows in the Figure 8A and in the higher magnification images in Figure 8C . Vascular encircling of MDA-IBC3 clusters in the in vitro platform is reminiscent of IBC tumors in vivo in both IBC patients ( Figure 8B ) and in patient derived xenograft (PDX) models of IBC [62, 63] . The newly formed endothelial sprouts continued to penetrate deeper and further into the collagen ECM in a disorganized manner, and the MDA-IBC3 emboli surrounded by the vessels grew larger as depicted by the white arrows in the DAY 16 panel and Figure 8B . Quantification of vessel sprouting over time showed a significant increase in sprout lengths and growth compared to Day 0, p<0.001, (Figure 8C ). This phenomenon was only observed in the presence of MDA-IBC3 cells and not in any of the other platforms. Figure 9 : Cytokine analysis of various angiogenic associated factors measured over a three week period. ANG2, VEGF-A, PDGF-bb, IL-8, IL-6, and MMP2 showed a significant increase in expression on Day 22 compared to earlier timepoints while bFGF and EGF both peaked on Day 7, *p<0.05.
Cytokine Analyses of Vascular Sprouting
Cytokine analysis of the perfusion media at outlet illustrated in Figure 9 was performed to gain a better understanding of the driving factors behind the sustained angiogenic sprouting. VEGF-A, ANG-2, PDGF-bb, IL-8, IL-6, and MMP2 expressions were significantly higher (p<0.05) on Day 22 compared to the earlier timepoints. VEGF-A expression was higher at the later timepoints (Day 7, 14 and 22) compared to 0 and IL-8 expression increased significantly on Day 14 and 22 compared to Day 0. bFGF and EGF both showed a similar trend with expression peaking on Day 7 (p<0.05) and then decreasing back to levels comparable to Day 0 on Day 14 and 22.
Discussion
In this study, we developed 3D in vitro vascularized tumor platforms to model the interactions of multiple aggressive breast tumor cell and stroma, specifically tumor-vasculature and tumor-ECM interaction. Tumor specific in vivo responses including increased vascular permeability, ECM remodeling, and vessel sprouting as a result of the tumor-stromal interaction were reproduced and we showed a differential response of the tumors in modulating these behaviors. After teasing out the differences between the different tumor cells, we investigated the vascular sprouting nature of MDA-IBC3 with the platform providing the first opportunity to spatially observe and quantify this behavior in vitro and were able to recreate and validate previously published in vivo phenotypes including endothelial sprouting, and vascular encircling of tumor emboli.
Tumor vasculature is characterized by the presence of leaky blood vessels which has been implicated in inefficient delivery of chemotherapies as well as playing a crucial role in tumor intravasation [64] [65] [66] [67] [68] [69] . We demonstrated the presence of triple negative MDA-MB-231 and SUM149 cells compromised the vascular barrier functions with formation of large pores and gaps in the endothelium as well as decreased endothelial coverage of the vessel. Previous studies demonstrated direct contact between MDA-MB-231 and endothelial cells disrupted endothelial monolayers and resulted in anoikis of endothelial cells [70] [71] [72] [73] [74] [75] [76] [77] . In contrast, MDA-IBC3, did not significantly alter the endothelium barrier function and maintained a confluent endothelium. The bright patches of red fluorescent signal in the F-actin stained images, as well as the increased coverage of the endothelium in MDA-IBC3/TIME in vitro vascularized platform, suggests increased proliferation of TIME cells as IBC cells are associated with high proliferation levels of endothelial cells [7, 25, 62, 78, 79] . In addition to increased proliferation, IBC is highly angiogenic with a significantly higher population of tumor infiltrating and proliferating endothelial cells compared to non-IBC cells [62, 79] which is evidenced with the sustained angiogenesis occurring and directed towards tumor cells in our MDA-IBC3/TIME in vitro platforms.
Vascular permeability is a measurement of the integrity and leakiness of the endothelium. Co-culture with SUM149 resulted in a significantly increased permeability when compared to the platform with TIME cells only. This phenomenon was also mirrored in the MDA-MB-231/TIME platform and followed results from multiple groups where introduction of highly invasive tumor cells increased permeability of the endothelium [76, [80] [81] [82] [83] [84] [85] [86] [87] . The increased vessel permeability correlates with the discontinuous expression of PECAM-1, a marker for endothelial cell-cell junctions used as a surrogate for permeability and leakiness, in the triple negative in vitro vascularized platforms of SUM149/TIME and MDA-MB-231/TIME whereas MDA-IBC3/TIME and TIME only in vitro vascularized platforms displayed a uniform expression. Both the SUM149 and MDA-MB-231 cells disrupt the endothelium resulting in gaps between endothelial cells allowing for dextran to cross into the collagen unhindered correlating with results seen in other experimental studies [70] [71] [72] [73] [74] [75] [76] [77] .
IBC tumors are highly angiogenic with increased expression of angiogenic factors as well as a larger density of vascular vessels compared to non-IBC tumors [23, 62, [88] [89] [90] [91] and as evidenced in our MDA-IBC3/TIME platforms (Figure 8 ). VEGF is an overexpressed angiogenic factor in IBC and known to influence endothelial growth and proliferation and interacts synergistically to induce angiogenesis [23, 55, [91] [92] [93] . van Golen et al determined increased levels of VEGF mRNA in IBC tumors vs non-IBC tumors [91] corresponding with the increased levels of VEGF expression in MDA-IBC3/TIME and SUM149/TIME in vitro vascularized platforms compared to MDA-MB-231/TIME. VEGF expression was highest in the MDA-IBC3/TIME platform, which displayed angiogenic sprouting of the vessel, compared to SUM149/TIME platform which was shown to be leakier with decreased endothelial coverage of the vessel no signs of vascular sprouting.
Co-culture of the tumor and endothelial cells not only affected the vascular integrity and cytokine expression, but also influenced ECM properties, specifically porosity. Invasive tumors modulate and breakdown the surrounding ECM in order to migrate through the TME and out into the surrounding tissue. Normal breast tissue is disorganized with random alignment of collagen fibers but in tumors, the collagen fibers are radially oriented and organized into thick bundles promoting invasive phenotype [94] . Analysis of SEM images of the acellular collagen matrix (data not shown) revealed a pore size of ~1 µm, much smaller than cell width. Pore sizes smaller than a cell's width induces degradation of the matrix through secretion of matrix metalloproteinases (MMPs) to allow for motility of cancer cells [95] [96] [97] [98] [99] [100] . Al-Raawi et al found an overexpression of MMPs by IBC carcinoma tissues [101] which are involved in degradation of collagen I and widening of pore size to allow for cell migration and invasion [98, 100, [102] [103] [104] [105] . Rizwan et al demonstrated an increased migratory and invasive behavior in SUM149 cells as well as increased levels of MMP9 in compared to MDA-MB-231 cells [18] . Higher proteolytic activity of IBC breast tumors compared to non-IBC tumors accounts for the significantly increased matrix porosity in the SUM149/TIME and MDA-IBC3/TIME in vitro vascularized platforms.
To the best of our knowledge, this is the first demonstration of vascular sprouting in a 3D in vitro platform sustained through interactions between tumor and endothelial cells without the influence of any exogenous supplements or additional stromal cells. Along with vessel sprouting, we saw the formation and growth of MDA-IBC3 tumor emboli enveloped by newly formed vascular vessels which is characteristic of in vivo IBC tumors. In an invasion independent metastasis mechanism proposed by Sugino et al, tumor clusters accessed blood vessels by being surrounded by the vessels rather than intravasation, similar to behavior seen in the MDA-IBC3/TIME vascularized breast tumor platforms ( Figure 8C ) [106] . Published work by Mahooti et al describe a phenotype of encircling vasculogenesis in the Mary-X IBC mouse model [63] , behavior reproduced by the endothelial sprouts in the in vitro platform encircling MDA-IBC3 cells in the matrix demonstrating this in vivo phenotype (Figure 8) . Analysis of cytokine expression in the MDA-IBC3/TIME platforms revealed a significant increase in the proangiogenic factors by Day 22 compare to Day 0 associated with significant amount of angiogenesis occurring at the later time point. While the highest expression of most of the growth factors, cytokine and MMPs measured was highest on DAY 22, bFGF and EGF both displayed similar trend in expression levels with the highest expression on Day 7. Additionally, we determined VEGF, known as an important angiogenic factor [107, 108] , to be a key contributor of angiogenesis in our system as continued increase in expression of VEGF paralleled the increase in angiogenic response in the MDA-IBC3/TIME platform.
There are some limitations to our study and the tumor platform presented. While the in vitro platforms developed in this study do not encompass the entire complexity of the tumor microenvironment and utilize immortalized endothelial cells, they provide an initial insight into the behavior of aggressive, metastatic breast tumors. Future experiments utilizing this platform can be expanded to incorporate stromal and immune cells known to influence tumor behavior. Additionally, we acknowledge that the size of the endothelial vessels is larger than the size of in vivo microvasculature, but the platform can be adapted to present a more comparable vessel with the use of smaller gauge needles for formation of the cylindrical vessels. We have conducted preliminary studies using needles to create smaller vessels but vessels below 200 µm using needle subtraction method are not very stable. Also, we have started preliminary work looking at the influence of macrophages, revealed to be important contributing factor in driving IBC phenotype, and observed their role in IBC intravasation and angiogenic response. Future experiments will include increasing cellular complexity of the stromal component of the in vitro vascularized platform to include mesenchymal stem cells, adipocytes, and fibroblasts.
Conclusion
3D in vitro vascularized platforms presented in this work allowed us to dynamically track and model the tumor-stroma interactions as well as determine the spatiotemporal response of these interactions on vascular permeability and matrix porosity for three different highly invasive and aggressive breast cancer phenotypes. Both the IBC tumor cells were more active in remodeling of the collagen ECM as well as secretion of proangiogenic and tumorigenic factor VEGF compared to non IBC MDA-MB-231, revealing potential targets for IBC therapeutics. For the first time, we induced angiogenic sprouting of the vascular endothelium and vascular surrounding of tumor emboli, characteristic behaviors of IBC tumors, purely through interactions between tumor and endothelial cells as well as recreated blood vessel leakiness, and increased matrix porosity representative of in vivo behavior of invasive tumors. Compared to current 3D in vitro tumor models that focus on recreating specific stages of tumor progression, the tumor platforms introduced here were able to model various stages in breast cancer progression including early signs of angiogenesis as well as modulation of tumor ECM and vasculature for migration and metastasis. With the vascularized breast tumor platforms, behavioral variations that are representative of in vivo tumors can be identified and differentiated as result of the different breast cancer cells. It allows for temporal and spatial imaging and identification of biological proteins and responses which may play a direct role in tumorigenesis and vascularization in vivo. They represent a useful tool for studying various aggressive breast cancers whose phenotype is driven by tumor-stromal interactions. These platforms can be further expanded to include increasingly complex cell type interactions to provide a tool by which we can further decipher the mechanisms behind development of these tumors and use the knowledge towards developing effective and targeted chemotherapies. 
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